The estimated Net Worth of David Carberry is at least $140 millier dollars as of 22 September 2021. Mr. Carberry owns over 50,000 units of Tyme Technologies Inc stock worth over $31,000 and over the last 7 years he sold TYME stock worth over $0. In addition, he makes $108,610 as Independent Director at Tyme Technologies Inc.
David has made over 4 trades of the Tyme Technologies Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 50,000 units of TYME stock worth $51,500 on 22 September 2021.
The largest trade he's ever made was buying 50,000 units of Tyme Technologies Inc stock on 22 September 2021 worth over $51,500. On average, David trades about 12,500 units every 69 days since 2017. As of 22 September 2021 he still owns at least 100,000 units of Tyme Technologies Inc stock.
You can see the complete history of Mr. Carberry stock trades at the bottom of the page.
David Carberry serves as Independent Director of the Company. He has been a member of our Board since March 2017. Mr. Carberry is a retired healthcare financial executive with over 40 years of experience in the industry. Most recently, from April 2012 to June 2016, Mr. Carberry was the Chief Financial Officer of Excellis Health Solutions, LLC, a consulting and software solutions company focused on the healthcare industry. Before that, Mr. Carberry was Chief Financial Officer of Aldagen, a biopharmaceutical company, from 2008 to 2011. Mr. Carberry also served in a number of financial oversight roles within Johnson & Johnson and related divisions between 1981 and 2008, including Vice President, Finance of Independence Technology L.L.C., Johnson & Johnson/Merck Consumer Pharmaceuticals, a joint venture, and Vice President, Finance of Johnson Health Care Systems, Inc., a healthcare account management and business services provider.
As the Independent Director of Tyme Technologies Inc, the total compensation of David Carberry at Tyme Technologies Inc is $108,610. There are 7 executives at Tyme Technologies Inc getting paid more, with James Biehl having the highest compensation of $1,500,980.
David Carberry is 67, he's been the Independent Director of Tyme Technologies Inc since 2017. There are 3 older and 15 younger executives at Tyme Technologies Inc. The oldest executive at Tyme Technologies Inc is Gerald Sokol, 77, who is the Independent Director.
David's mailing address filed with the SEC is C/O TYME TECHNOLOGIES, INC., 1 PLUCKEMIN WAY - SUITE 103, BEDMINSTER, NJ, 07921.
Over the last 7 years, insiders at Tyme Technologies Inc have traded over $11,656,990 worth of Tyme Technologies Inc stock and bought 384,831 units worth $412,502 . The most active insiders traders include Steve Hoffman, Michael Demurjian et Douglas A Michels. On average, Tyme Technologies Inc executives and independent directors trade stock every 8 days with the average trade being worth of $15,104. The most recent stock trade was executed by Michael Demurjian on 6 September 2022, trading 160,000 units of TYME stock currently worth $40,000.
Tyme Technologies, Inc., is an emerging biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the Company's therapeutic approach is designed to take advantage of a cancer cell's innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body's natural immune system.
With the development of TYME-18 and TYME-19, the Company believes that it is also emerging as a leader in the development of bile acids as potential therapies for cancer and COVID-19.
Tyme Technologies Inc executives and other stock owners filed with the SEC include: